Prescription Pricing for the People Act of 2025
This bill appears to be dead.
No action recorded in 1 year, 3 months. The structural status reflects an earlier milestone, not current activity.
Prescription Pricing for the People Act of 20 25 This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs. The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs. The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations. Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Filed in the Senate
This senate bill has been filed and is working its way through Congress. It will need to pass both the Senate and the House, then be signed by the President to become law.
Who introduced this
Ask AI About This Bill
Get plain-language answers with direct quotes from the bill text.
Your Representatives
Enter your address to see how your representatives voted on this bill.
Your address is only used to find your district and is never saved. See how it works
Votes
Public Opinion
No votes yet — be the first to weigh in.
to cast your vote
Your voice matters — let representatives know where you stand.
Comments
No comments yet. to be the first to weigh in.